- Home
- PIII vs OKUR Comparison
PIII vs OKUR Comparison
Compare PIII & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- OKUR
- Stock Information
- Founded
- PIII 2015
- OKUR 2011
- Country
- PIII United States
- OKUR United States
- Employees
- PIII N/A
- OKUR N/A
- Industry
- PIII Medical/Nursing Services
- OKUR
- Sector
- PIII Health Care
- OKUR
- Exchange
- PIII Nasdaq
- OKUR NYSE
- Market Cap
- PIII 30.8M
- OKUR 34.9M
- IPO Year
- PIII N/A
- OKUR N/A
- Fundamental
- Price
- PIII $6.62
- OKUR $2.88
- Analyst Decision
- PIII Buy
- OKUR Strong Buy
- Analyst Count
- PIII 2
- OKUR 4
- Target Price
- PIII $16.25
- OKUR $32.25
- AVG Volume (30 Days)
- PIII 5.1K
- OKUR 335.0K
- Earning Date
- PIII 05-15-2025
- OKUR 05-06-2025
- Dividend Yield
- PIII N/A
- OKUR N/A
- EPS Growth
- PIII N/A
- OKUR N/A
- EPS
- PIII N/A
- OKUR N/A
- Revenue
- PIII $1,485,192,000.00
- OKUR N/A
- Revenue This Year
- PIII N/A
- OKUR N/A
- Revenue Next Year
- PIII $6.01
- OKUR N/A
- P/E Ratio
- PIII N/A
- OKUR N/A
- Revenue Growth
- PIII 9.79
- OKUR N/A
- 52 Week Low
- PIII $6.47
- OKUR $1.70
- 52 Week High
- PIII $33.73
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- PIII 30.04
- OKUR N/A
- Support Level
- PIII $6.47
- OKUR N/A
- Resistance Level
- PIII $7.45
- OKUR N/A
- Average True Range (ATR)
- PIII 0.29
- OKUR 0.00
- MACD
- PIII -0.09
- OKUR 0.00
- Stochastic Oscillator
- PIII 8.26
- OKUR 0.00
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.